Compare DWSN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | ICCC |
|---|---|---|
| Founded | 1952 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 93.1M |
| IPO Year | 1995 | 1995 |
| Metric | DWSN | ICCC |
|---|---|---|
| Price | $2.23 | $10.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 88.8K | 10.0K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.73% | N/A |
| EPS Growth | 53.85 | 53.85 |
| EPS | 0.14 | ★ 0.41 |
| Revenue | ★ $145,773,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $16.00 | $25.76 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.50 | $4.52 |
| 52 Week High | $7.85 | $12.10 |
| Indicator | DWSN | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 27.39 | 63.42 |
| Support Level | $2.03 | $9.42 |
| Resistance Level | $2.39 | $10.75 |
| Average True Range (ATR) | 0.22 | 0.24 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 8.64 | 89.13 |
Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.